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Angiographic, angioscopic and pathologic reports have beatslmin, p = NS). In patients with intracoronary throm- 
recently demonstrated a high incidence of intracoronary bus, the ischemic pacing threshold increased 26 f 7 beats/ 
thrombus in patients with unstable angina. To determine min with rt-PA treatment versus 0 + 3 beats/min with 
if thrombolysis could be beneficial when combined with placebo (p = 0.004). In contrast, in patients without 
maximal medical therapy, 40 patients with rest angina, thrombus, there was no difference in ischemic pacing 
angiographically documented coronary artery disease threshold increments between treatment groups (7 + 11 
and pacing-induced ischemia were randomly assigned to beats/min for rt-PA versus 6 + 5 beatslmin for placebo, p = 
intravenous recombinant tissue-type plasminogen activator NS). Percent diameter stenosis in the ischemia-related 
(rt-PA, 150 mg/S h) or placebo in a prospective double- artery decreased from 71 -C 4% to 63 2 6% (p = NS) in 
blind trial. All patients received nitrates, a beta-adrenergic patients treated with r&PA and from 70 + 4% to 67 f 5% 
blocking agent, a calcium channel blocker, aspirin and (p = NS) in patients treated with placebo. There were no 
heparin. Pacing thresholds for ischemia and quantitative significant differences in clinical outcome or incidence of 
coronary stenosis were measured before and after infusion asymptomatic ST segment change between treatment 
of the study medication. groups. 
Intracoronary thrombus was identified angiographically 
before infusion of the study medication in 16 patients; 7 
received rt-PA and 9 received placebo. The ischemic pacing 
threshold in patients treated with r&PA increased from 112 
f 4 beats/min at baseline to 127 f 5 beats/min (p = 0.007) 
by the end of the infusion versus an insignificant change in 
patients who received placebo (from 116 f 4 to 119 + 4 
Thus, infusion of r&PA in patients with unstable angina 
can produce additional benefit when combined with maxi- 
mal medical therapy. However, the benefit appears to be 
limited to patients with angiographic evidence of intracor- 
onary thrombus. 
(J Am Co11 Cardiol1989;13:434-41) 
The medical management of unstable angina has evolved 
over the past 20 years to include nitrates, beta-adrenergic 
blocking agents, calcium channel blockers and aspirin (l-5). 
The variety of this therapy reflects, in part, the probable 
multifactorial pathophysiology of the syndrome. Progressive 
encroachment on the coronary lumen by atherosclerotic 
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plaques, coronary vasospasm and platelet deposits have all 
been implicated as etiologic mechanisms (6-8). 
Recent studies have suggested that intracoronary throm- 
bus may also have an important role in unstable angina. 
Angiographic, angioscopic and pathologic reports (9-15) 
have demonstrated intracoronary thrombus in the ischemia- 
related artery in many, if not all, patients with this syn- 
drome. Thrombolysis directed at this common pathophysiol- 
ogy would appear to have therapeutic potential. In fact, 
infusion of streptokinase and recombinant tissue-type plas- 
minogen activator (rt-PA) in small numbers of patients has 
produced symptomatic and angiographic benefit (10,16,17). 
This prospective, randomized, placebo-controlled, dou- 
ble-blind trial was designed to determine if thrombolytic 
therapy with intravenous &PA could, when combined with 
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conventional medical management, provide additional ben- 
efit to patients with unstable angina. Four end points were 
examined: 1) change in threshold for pacing-induced ische- 
mia, 2) coronary thrombolysis as determined by quantitative 
angiography, 3) clinical outcome, and 4) incidence of tran- 
sient ischemic events as detected by continuous ST segment 
analysis. 
Methods 
Patient selection. Patients between the ages of 18 and 80 
years with chest pain at rest consistent with myocardial 
ischemia were eligible for this study. Exclusion criteria were 
recent (within 1 week) enzymatic evidence of an acute 
myocardial infarction as defined by a greater than twofold 
elevation in baseline serum creatine kinase level, a history of 
significant bleeding diathesis. gastrointestinal or genitouri- 
nary bleeding within 4 months, a history of head trauma or 
stroke within 3 months or major surgery on internal organs 
within 2 weeks. All patients gave written informed consent 
as approved by the University of Michigan Hospital Com- 
mittee for Human Subjects. 
Primary inclusion criteria in addition to angina at rest 
were: 1) angiographic evidence of critical coronary disease, 
and 2) electrocardiographic evidence of ischemia during 
incremental cardiac pacing. Therefore, before inclusion in 
the protocol, all patients underwent diagnostic coronary 
angiography and a pacing study to determine their ischemic 
threshold. Patients with left main coronary artery stenosis 
>50% and patients with normal coronary arteries (that is, no 
artery with >50% stenosis) were excluded from the study. 
Patients with an ischemic pacing threshold >150 beatslmin 
were also excluded. 
Study design. On admission, patients received intensive 
antianginal therapy consisting of diltiazem (at least 60 mg 
orally every 6 h), intravenous nitroglycerin or oral isosorbide 
dinitrate every 6 h (unless systolic blood pressure was < 110 
mm Hg), oral propranolol every 6 h (unless heart rate was 
~50 beatslmin), aspirin (325 mg orally per day) and heparin 
(intravenously as a 5000 U bolus, followed by a continuous 
infusion of 1000 U/h). Diagnostic coronary angiography was 
performed within 36 h of admission, and a transvenous 
temporary pacing wire was placed in the right ventricular 
apex at the time of cardiac catheterization. 
Cardiac pacing was begun at a heart rate of 70 to 100 
beats/min and serially increased at 3 min intervals in incre- 
ments of 10 beats/min until the patient developed typical 
angina1 chest pain, significant ST segment changes or a heart 
rate of 150 beatsimin. A 12 lead electrocardiogram (ECG) 
was obtained immediately after each 3 min pacing increment 
during supraventricular rhythm. New ST segment depres- 
sion > 1.5 mV at 80 ms after the J point, T wave inversion or 
pseudonormalization was considered to be a significant 
change. Criteria for a positive pacing study were the devel- 
opment of typical angina1 discomfort or significant ST seg- 
ment changes. 
All suitable patients with chest pain at rest, significant 
coronary artery stenoses and pacing-induced ischemia were 
randomized within 24 h of angiography to receive either 
rt-PA (150 mg intravenously over 8 h) or a placebo infusion. 
The dose of rt-PA was infused at 60 mglh over the 1st h, 20 
mglh over the 2nd and 3rd h and 10 mg/h during the final 5 h 
of infusion. The rt-PA was a predominant single chain 
preparation (Genentech). Randomization was determined 
from a sequence developed by the Genentech Corporation 
central laboratory with use of a random number algorithm to 
yield blocks with equal allocation to each treatment in 
groups of IO. The block size was not provided to the 
investigators, and no attempt was made to stratify baseline 
patient characteristics. Only unidentified vials and a sealed 
envelope containing a scratch-away film card were provided 
for each patient. In the event of a medical emergency, 
removal of the film revealed the individual patient therapy. 
The randomization sequence was not revealed until all 
enrollment and end point data analysis were complete. 
Study end points. The primary end point of the study was 
the pacing threshold for ischemia. Repeat pacing tests were 
performed during the last 2 h of study medication infusion 
and 12 to 24 h after termination of the infusion. Incremental 
pacing was continued until the patient developed typical 
angina1 chest pain, significant ST segment changes or a heart 
rate of 180 beats/min. 
Coronary arteriography. Interventional cardiac catheter- 
ization was performed within 12 to 24 h after infusion of the 
study medication. Cineangiograms from the diagnostic cath- 
eterization were reviewed and identical projections of the 
ischemia-related vessel were obtained for comparison. Pa- 
tients with a residual high grade coronary stenosis after 
thrombolytic therapy underwent angioplasty. The stenotic 
artery was considered to be ischemia-related in patients with 
single vessel disease. In patients with multivessel disease 
(multiple stenoses > 50%), the ischemia-related artery was 
determined by correlation with pacing-induced or rest ST 
segment changes. Qualitative analysis of the ischemia- 
related artery was determined from the outlines of the 
stenotic lesion. Intracoronary thrombus was defined as a 
definite contrast filling defect in at least two orthogonal or 
hemiaxial views or total occlusion of the involved artery 
with convex or hazy margins and contrast staining during 
angiography. The presence or absence of thrombus was 
determined independently by two observers blinded to pa- 
tient identity, therapy and the effects of therapy. 
Quantitative analysis of the degree of coronary stenosis 
was performed using an automated edge detection computer 
system (18). End-diastolic frames were chosen from the 
projection demonstrating the most severe stenosis. Images 
were digitized into 256 x 256 eight-bit matrices, with a tine 
film projection equipped with a primary beam splitter cou- 
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pled to a fixed gain video camera and a video to digital 
converter. Digital storage and processing were performed 
on a DPS 4100C computer (ADAC Laboratories) using an 
operator-selected field of interest. Percent stenosis and 
minimal absolute calculated lumen area were determined. 
All quantitative angiographic results reported were digitally 
analyzed. 
Table 1. Baseline Preinfusion Data in 40 Patients 
Monitoring. Patients were continuously monitored for 
recurrence of chest pain. Patients with rest angina lasting 
>20 min during or after the infusion were considered to have 
reached a negative end point. The study medication was 
unblinded, and those patients receiving a placebo infusion 
were given rt-PA (I.50 mg intravenously over 8 h). Patients 
with prolonged chest pain receiving rt-PA underwent emer- 
gency coronary angioplasty or coronary artery bypass sur- 
gery. 
No. of patients 
Age (yr) 
Male/female 
Previous infarction 
Multivessel disease 
Duration of unstable 
angina (days) 
rt-PA Placebo 
20 20 
58.8 I! 2.5 58.1 ? 2.2 
15l.s 1311 
6 8 
I5 II 
8.8 ? 1.7 6.6 * 1.4 
Ischemic-related 
artery stenosis (F&i) 
71 A4 70 + 4 
Intrdcoronary 
thrombus 
7 9 
lschemic pacing 
threshold 
(beatsimin) 
II2 t 4 II3 L 5 
Probability (p) values were nonsignificant for all variables. 
Continuous two lead (aVF and V,) electrocardiographic 
(ECG) Holter recordings were obtained from the time of 
admission. ST segment analysis was performed with an 
Instruments for Cardiac Research 6201 Holter system. New 
ST segment depression >I.5 mV at 80 ms after the J point 
lasting for 230 s was considered ischemic. 
bles were made using linear regression analysis. Data are 
reported as the mean value 2 1 SEM. Probability (p) values 
>0.05 were considered not significant (NS). 
Coagulation studies. Plasma levels of fibrinogen and fi- 
brin degradation products were collected at baseline and at 
2,8 and 24 h after the start of the study medication infusion. 
Samples were collected on 0.01 M citrate and 200 klU/ml 
aprotonin (Trasylol). The Clauss (19) and Merskey (20) 
methods were used to determine levels of fibrinogen and 
fibrin degradation products, respectively. 
Results 
Study patients. Between March 26, 1986 and April 1, 
1987, the 40 patient study group was recruited and equally 
randomized to treatment with rt-PA or placebo. There were 
no significant differences in baseline variables between the 
groups (Table 1). 
Hemorrhage was classijied as major or minor according 
to the site of bleeding and the amount of blood loss. 
Intracranial bleeding or a decrease in hematocrit > 10% was 
considered major hemorrhage. Minor hemorrhage was de- 
fined as the development of hematemesis, hematochezia, 
hematuria, hemoptysis, epistaxis or a decrease in hematocrit 
>5 and <lo%. 
Statistical evaluation. Sample size calculations were 
based on the following assumptions: 1) The variance in 
pacing thresholds of a group of patients with active unstable 
angina would be approximately I5 beatsimin. 2) An improve- 
ment of 15 beatslmin in pacing threshold would occur in the 
rt-PA treatment group. 3) No change in pacing threshold 
would occur with placebo. Therefore, a total sample size of 
40 patients with equal allocation was required to achieve a 
statistical power of 0.90 with alpha error ~0.05. 
tntracoronary thrombus was ident$ed angiographically 
before infusion of the study medication in 16 patients, 7 
assigned to receive rt-PA and 9 to placebo. Four patients had 
complete occlusion of the involved artery. The two observ- 
ers agreed on the presence or absence of angiographic 
thrombus in all cases. Patients with thrombus could not be 
identified before angiography on the basis of the clinical 
frequency or duration of rest angina or the degree of ST 
segment change with spontaneous or pacing-induced ische- 
mia. However, among 31 patients with rest angina occurring 
within 72 h of angiography, 16 had intracoronary thrombus 
in the involved artery, whereas none of 9 had thrombus 
when angiography was performed after 72 h from the last 
episode of chest pain (p = 0.027). Among patients with 
intracoronary thrombus, clot was present only in the in- 
volved artery, and there were no differences in baseline 
variables between treatment groups. 
Analysis of all variables between and within groups was Ischemic pacing thresholds. Two patients receiving rt-PA 
based on the intention to treat principle. Changes in ische- and one receiving placebo developed rest angina during 
mic pacing threshold and quantitative coronary stenosis in blinded infusion and further pacing studies were not per- 
each treatment group were compared with a two-tailed formed. An increase in serum creatine kinase in one patient 
paired t test. Differences between groups were analyzed with randomized to placebo was detected during blinded infusion, 
a two-tailed Student’s t test. The differences in incidence of and follow-up pacing studies in this patient were also de- 
recurrent angina and asymptomatic ST segment depression leted. Thus, thresholds for pacing-induced ischemia were 
between patients treated with rt-PA and placebo were deter- determined in 18 patients in each treatment group at the end 
mined with Fisher’s exact test. Correlations between varia- of the study medication infusion. 
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BASELINE INFUSION BASELINE INFUSION 
Figure 1. Ischemic pacing thresholds before and after treatment 
with recombinant tissue-type plasminogen activator (rt-PA) (n = 18) 
or placebo (n = 18). Asterisks = group mean. 
Ischcmic pucing thresholds in patients treuted with rt-PA 
increased from I 12 t 4 at baseline to 127 L 5 beatsimin (p = 
0.007) by the end of the infusion versus an insignificant 
change in patients who received placebo (from 116 t 4 to II9 
2 4 beatslmin, p = NS) (Fig. I). The differences between 
treatment groups did not reach statistical significance (p = 
0.06). However, in patients with intracoronary thrombus, 
the ischemic pacing threshold increased 26 ? 7 beats/min in 
the seven patients treated with rt-PA versus 0 t 3 beatsimin 
in the nine patients who received placebo (p = 0.004) (Fig. 
2). In contrast, in the patients without thrombus, there was 
no difference in ischemic pacing threshold increments be- 
Figure 2. Increments in ischemic pacing thresholds before and at 
the end of study medication infusion. Patients are grouped by the 
presence (n = 7) or absence (n = 9) of angiographically evident clot. 
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Figure 3. Increments in ischemic pacing thresholds before and 12 to 
24 h after infusion of the study medication. Patients are grouped by 
the presence (n = 8) or absedce (n = IO) of angiographically evident 
clot. 
tween treatment groups; 7 k II beats/min for rt-PA versus 6 
k 5 beats/min for placebo (p = NS). Ischemic pacing 
threshold was determined in four patients with intracoronary 
thrombus in each treatment group I2 to 24 h after blinded 
infusion. In this subset, the pacing threshold for ischemia 
increased 32 f 7 beats/min in the four patients who received 
rt-PA, whereas it decreased 8 ~tr I4 beatsimin in the four who 
received placebo (p = 0.03) (Fig. 3). 
Angiographic stenosis. Quantitative coronary angiogra- 
phy could not be performed because of technically inade- 
quate views in six patients, five who received rt-PA and one 
who received placebo. In the 34 patients with adequate 
projections, percent diameter stenosis in the ischemia- 
related artery decreased from 71 ? 4 to 63 t 6% (p = NS) in 
patients treated with rt-PA and from 70 + 4 to 67 5 5% (p = 
NS) in those treated with placebo (Fig. 4). In the I6 patients 
with intracoronary thrombus, the percent stenosis decreased 
from 82 t 7 to 73 2 10% (p = NS) in the rt-PA group and 
from 81 t 7 to 79 -t 7% (p = NS) in the placebo group (Fig. 
5). These differences between treatment groups for all pa- 
tients and for the subgroup with thrombus were not statisti- 
cally significant. There was also no significant correlation 
between changes in the ischemic pacing threshold and 
alterations in angiographic stenosis measured either as per- 
cent diameter (r = 0.31, p = 0.08) or coronary lumen area 
(r = 0.29, p = 0.11). 
Clinical course. Five patients developed recurrent symp- 
toms at rest during the observation period; four were treated 
with rt-PA and one received placebo. Two of the four 
patients who received rt-PA had a myocardial infarction and 
died during hospitalization, one after emergency coronary 
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Figure 4. Quantitative percent diameter stenosis before and after 
(POST-Rx) treatment with recombinant tissue-type plasminogen 
activator (rt-PA) (n = 16) or placebo (n = 19). 
artery bypass grafting. None of the patients with recurrent 
symptoms had evidence of intracoronary thrombus. These 
differences in clinical outcome were not statistically signifi- 
cant. Two additional patients who received placebo had an 
asymptomatic increase in serum creatine kinase during or 
after infusion of the study medication, and the protocol was 
discontinued. In both patients, infarction was presumed to 
have begiln before drug infusion. 
ST segment analysis. Technically adequate two channel 
Holter ECG recordings were obtained in 32 patients before, 
3 1 patients during and 19 patients after infusion of the study 
medication. In these patients, an average of 8.0 h of data per 
patient was analyzed before infusion compared with 18.5 h 
Figure 5. Quantitative percent diameter stenosis before and after 
(POST-Rx) treatment with recombinant tissue-type plasminogen 
activator @t-PA) (n = 6) or placebo (n = 8) in patients with 
angiographically evident clot. 
rt-PA PLACEBO 
p=NS p=NS 
4oJ 
BASELINE POST-h BASELINE POST-Rx 
per patient during and after the administration of the study 
drug. 
Five patients had transient asymptomatic ST segment 
changes before blinded infusion; two of the five had clot 
demonstrated on angiography. Four were treated with rt-PA 
and one received placebo. In three of the four patients who 
received r&PA, adequate Holter ECG recordings were ob- 
tained after therapy was begun and demonstrated no further 
transient ST segment changes. In the patient treated with 
placebo, transient asymptomatic ST depression persisted 
after blinded infusion. Three additional patients developed 
transient ST changes, in two after infusion with r&PA and in 
one after placebo. 
Coagulation studies. Major hemorrhage or intracranial 
bleeding was not a complication in the study. Minor hemor- 
rhage requiring transfusion occurred in five patients treated 
with rt-PA and in no patients receiving placebo. Minor 
hemorrhage also occurred in five additional patients treated 
with rt-PA (hematuria in two, hematemesis in one, he- 
moptysis in one and epistaxis in one) and in one patient who 
received placebo (epistaxis). Oozing from puncture sites 
occurred in 13 patients treated with rt-PA and in 2 who 
received placebo. Plasma fibrinogen levels did not change 
significantly in the placebo group, but decreased 53 -+ 10% 
from baseline to the nadir at 8 h in the rt-PA group (p < 
0.001). 
Discussion 
Clinical benefit of thrombolytic therapy in unstable angina. 
These results demonstrate that thrombolytic therapy with 
rt-PA can produce additional benefit in patients with unsta- 
ble angina who are already receiving maximal medical 
therapy. By the end of drug infusion in this study, the pacing 
threshold for ischemia had increased bj, 14 ? 5 beatslmin 
with rt-PA versus only 3 2 3 beats/min in the placebo group. 
Twelve to 24 h later, the increment in ischemic pacing 
thresholds was 17 2 8 versus 1 ? 6 beats/min in the rt-PA 
and placebo groups, respectively. 
This is the first trial of &PA in patients with unstable 
angina who were also receiving maximal medical therapy. 
Given the efficacy of conventional treatment, a clinical 
benefit might be difficult to demonstrate in a small trial. 
Nevertheless, the increment in ischemic pacing threshold 
after rt-PA infusion suggests that thrombolysis can be useful. 
Changes in ischemic thresholds have been demonstrated 
after other effective interventions. Both angioplasty and 
coronary artery bypass surgery in patients with this syn- 
drome have resulted in similar increments in pacing thresh- 
old (21,22). These increases in the ischemic threshold level 
correlate with changes in exercise tolerance and, thus, imply 
a beneficial effect of thrombolysis in unstable angina (22-25). 
The pacing test has limitations in assessing the multifactorial 
pathophysiology in this syndrome. Changes in the vasomo- 
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tor tone of some lesions may produce ischemia spontane- 
ously, and similar vasospasm may not be provoked during 
pacing. However, because this trial included only patients 
with a significant stenosis in the involved artery and ische- 
mia provoked by pacing, the trial selected patients who 
could be assessed with the pacing test. 
Role of intracoronary thrombus. The presence of intraco- 
ronary thrombus detected on angiography appeared to iden- 
tify the subgroup of patients in whom lytic therapy was 
successful. Identification was reproducible given the criteria 
used in this study, and the incidence was comparable with 
that observed in other series (15,26). In patients with intra- 
coronary thrombus, the ischemic pacing threshold increased 
26 -+- 7 beatslmin in the rt-PA group versus 0 ? 3 beatsimin 
in the placebo group. In patients without thrombus, there 
was no difference in pacing threshold increments between 
treatment groups (7 + 1 I versus 6 ? 5 beats/min for rt-PA 
versus placebo). The striking difference in therapeutic re- 
sponse between patients with and without intracoronary 
thrombus suggests that rt-PA has a specific action in lysing 
thrombus and is useful only in the subgroup with an angio- 
graphically detectable clot. For these patients, thrombolysis 
may be beneficial not only in decreasing coronary stenosis, 
but also in removing the focus for platelet deposition and its 
potential for vasospasm and additional thrombosis. 
The power of angiographically identified intracoronary 
thrombus to predict the therapeutic response to rt-PA is 
somewhat surprising because the identification criteria for 
thrombus are subjective and have been previously reported 
to be insensitive compared with direct angioscopy. Sherman 
et al. (I 5) visualized intracoronary thrombus during angio- 
scopy in seven patients with unstable angina, of whom only 
one had angiographic evidence of clot. Their study was 
confounded by a significant delay between angiography and 
angioscopy (ranging from 10 to 480 h), allowing the sponta- 
neous appearance of thrombus to potentially complicate the 
correlation between techniques. Nonetheless, intracoronary 
thrombus could have been suspected in the present study in 
many of the patients without angiographic evidence. Why 
thrombolysis would not have been effective in these patients 
with more subtle clot is unknown. One possible explanation 
is that angiographically visible thrombus has a larger mass 
and thereby directly compromises the arterial lumen. A 
larger thrombus may also have a greater surface area for 
secondary activation of platelets. Finally, angiographic vis- 
ibility of the thrombus may indicate partial detachment of 
the clot from the vessel wall, making it mechanically more 
volatile and, thus, more likely to produce symptoms. What- 
ever the pathophysiologic role, angiographically visible in- 
tracoronary thrombus appears to identify an important ther- 
apeutic subset of patients with unstable angina. 
Clinicul characteristics could not be used to distinguish 
patients with angiographic intracoronary thrombus before 
catheterizution in this study. However, in the nine patients 
whose catheterization was delayed for >72 h after their last 
spontaneous symptoms, none had intracoronary thrombus. 
In these patients, the prolonged period without symptoms 
may have implied spontaneous thrombolysis and, thus, 
resolution of the underlying pathophysiologic trigger. Spon- 
taneous thrombolysis coinciding with resolution of clinical 
unstable angina has been recently demonstrated in serial 
angiographic studies (27). This suggests that thrombolytic 
therapy would be useful in patients with persistent or pro- 
gressive symptoms but would have little potential benefit 
after the acute syndrome has resolved. 
Correlation between pacing ischemic threshold and angio- 
graphic thrombus. Although there was a significant increase 
in pacing threshold, this study did not demonstrate a statis- 
tically significant lessening of angiographically demonstrated 
stenosis with rt-PA in patients with or without intracoronary 
thrombus. However, there was a trend toward reduction in 
diameter stenosis in all patients treated with rt-PA of 9 ? 6% 
versus 3 ? 5% in patients who received placebo. The small 
sample size selected for the variability in pacing threshold 
may have impaired our trial’s ability to achieve statistical 
power in analyzing this variable. In addition. the contribu- 
tion of intracoronary thrombus to the total coronary stenosis 
may have been relatively minor in some patients and, 
therefore. difficult to detect. Finally, spontaneous throm- 
bolysis may have occurred in some patients receiving pla- 
cebo, thereby reducing the ability to resolve intergroup 
differences. 
The indiliduul changes in ungiographic stenosis did not 
correlate bcith increments in ischemic prrcing thresholds. 
This lack of correlation is most likely attributable to the 
limits of resolution in determining the extent of coronary 
stenosis. The architectural topography of stenotic lesions is 
known to produce turbulent reductions in flow that differ 
from those predicted by minimal percent diameter stenosis 
or luminal area (28). The extent and significance of a stenosis 
may be better determined by measuring the ischemic thresh- 
old under the stress of pacing. However, in the absence of 
other markers of ischemia and in a small study group, the 
relative clinical importance of these variables cannot be 
determined. 
In contrast to previous studies and the improvement in 
pacing threshold in this trial, a clinical benefit in patients 
treated with rt-PA could not be demonstrated. Four rt-PA- 
treated patients versus one placebo-treated patient devel- 
oped recurrent symptoms at rest, and two of the former 
patients had a myocardial infarction and eventually died. 
Although these numbers did not achieve statistical signifi- 
cance, they emphasize the need to restrict administration of 
this drug to those with the greatest potential benefit. 
Asymptommtic ST segment changes bvere infrequent in 
this trirrl. In patients with asymptomatic ischemia, rt-PA 
appeared to eliminate their recurrence. However, the num- 
ber of patients and the frequency of events were too small to 
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support any conclusions. This low incidence of asympto- 
matic ischemia is in contrast to previous findings (29) and 
may reflect maximal medical therapy and patient selection. 
Comparison with previous studies. Clinical benefit from 
thrombolytic therapy in unstable angina has been reported 
by other investigators, but none used maximal medical 
therapy. Lawrence et al. (16) found that the addition of 
intravenous streptokinase reduced the incidence of subse- 
quent infarction and sudden death in patients treated with 
oral anticoagulants. However, the only other medical ther- 
apy was beta-adrenergic blockade in half of the patients and, 
because the cardiovascular events occurred an average of 46 
days after the streptokinase infusion, the relation between 
the clinical benefit and the lytic therapy was unclear. Man- 
delkorn et al. (10) used intracoronary streptokinase in nine 
patients with unstable angina and demonstrated recanaliza- 
tion or a reduction in the degree of stenosis in four, but the 
study was not placebo-controlled and did not correlate 
thrombolysis with clinical benefit. In a recent placebo- 
controlled trial, Gold et al. (26) found that the incidence of 
recurrent symptoms in unstable angina was reduced in those 
who received intravenous rt-PA; clinical benefit appeared to 
correlate with the absence of angiographically visualized 
thrombus after treatment. However, none of the patients 
received aspirin, and the incidence of recurrent symptoms in 
the control group (45%) was much higher than that reported 
in other trials (5) of maximal medical therapy. In the present 
study, the control group had a 5% incidence rate of recurrent 
symptoms and, thus, it was not possible to demonstrate 
clinical benefit from thrombolytic therapy in a trial of this 
size. 
Implications. On the basis of the results of the present 
study and previous trials, we conclude that infusion of rt-PA 
in patients with unstable angina can produce additional 
benefit when combined with maximal medical therapy. How- 
ever, the benefit appears to be limited to patients with 
angiographic evidence of intracoronary thrombus. Further 
trials to determine the role of thrombolysis in unstable 
angina are necessary and should consider limiting treatment 
to the subset with angiographically visible intracoronary 
thrombus to obtain a maximal benefit to risk ratio. 
We acknowledge the excellent assistance of Ray Worden in determining 
quantitative coronary stenosis, and of Linda M. Kelley and Mildred Herman 
in preparing the manuscript. 
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